Bajaj Healthcare is entering into a definitive Contract Development and Manufacturing Organization (CDMO) contract with UK/EU based companies for 15 new active pharmaceutical ingredients (APIs). This is in addition to 15 molecules for which the company entered the contract with UK/EU based clients on February 27, 2024. The new CDMO pipeline has a mix of, off Patent Generic APIs as well as APIs which are still under patent.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
